RNA Outsourcing Resources

  1. Clinical Research Is A Delicate Ecosystem 4/18/2024

    Making the right outsourcing decision can significantly contribute to the success and growth of your program, providing essential support and resources that empower it to thrive in its objectives and endeavors.

  2. High-Throughput Platform Propels Gene Editing Therapy Research 3/1/2024

    Explore the potential of polymeric nanoparticles (PNPs) as an alternative to viral vectors. PNPs offer design flexibility, enabling larger payloads, targeted release, and minimized side effects.

  3. Tackling Antimicrobial Resistance 5/14/2024

    Learn how three companies collaborated to develop a new antibiotic to address the increasing development of antimicrobial resistance (AMR) that threatens the global health landscape.

  4. xRNA Production: The Economic Case For Continuous Manufacturing 10/31/2025

    See how a continuous manufacturing platform streamlines production to days, uses real-time quality control, and dramatically cuts costs to accelerate access to new therapies.

  5. What Sponsors Get Wrong When Selecting A CRO 3/9/2026

    Gene therapy immunogenicity requires platforms, judgment, and regulatory fluency beyond ADA norms. Relying on biologics criteria creates gaps; CGT expertise ensures reliable, interpretable results.

  6. Is Not Using A CDMO Slowing Down Your Process Development? 4/27/2020

    Consider what process development capabilities you have versus what you could possibly gain from working with a CDMO to not only be successful but also improve your chances of getting to market sooner.

  7. What Is The Role Of CROs In Drug Development? 5/13/2025

    CROs are not just facilitators but strategic innovators essential for delivering new therapies to patients efficiently and safely.

  8. The Shift Toward Flexible FSP Models 11/13/2025

    Flexible FSP models are reshaping clinical outsourcing by offering sponsors scalable, cost-predictable partnerships that preserve control, enhance quality, and support long-term strategic goals.

  9. The M.O. Behind Choosing A CDMO: Three Considerations For New Drug Developers 11/29/2021

    The greatest challenge in drug development can be finding a team capable of carrying a molecule through the complexities that lie between the research lab and the patient’s bedside. Discover three considerations that build a foundation for partnership.

  10. Navigating Challenges In Progressing Breakthrough RNA Therapeutics 5/14/2024

    RNA therapeutics hold immense promise for precision treatment, but their development faces challenges. A CDMO with adaptable platforms and flexible timelines can help reduce time and costs.